Related Experiment Video
Updated: Aug 11, 2026
10:52
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
Published on: March 30, 2018
Splenic marginal zone lymphoma: a prognostic model for clinical use
Luca Arcaini1, Mario Lazzarino, Nora Colombo
1Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, 27100 Pavia, Italy. luca.arcaini@unipv.it
Blood
|February 24, 2006
Summary
A new prognostic index using hemoglobin, lactate dehydrogenase, and albumin levels can predict outcomes for splenic marginal zone lymphoma patients. This tool helps tailor treatment intensity for better patient management.
Area of Science:
- Hematology
- Oncology
- Clinical Research
Background:
- Splenic marginal zone lymphoma (SMZL) is a rare non-Hodgkin lymphoma.
- Accurate prognostic factors are crucial for guiding treatment decisions in SMZL patients.
Purpose of the Study:
- To assess the outcomes of splenic marginal zone lymphoma.
- To identify independent prognostic factors for cause-specific survival (CSS) in SMZL.
- To develop a novel prognostic index for SMZL.
Main Methods:
- Retrospective analysis of 309 SMZL patients.
- Univariate and multivariate analyses to identify prognostic factors.
- Development of a risk stratification model based on key clinical parameters.
Main Results:
- The 5-year CSS rate for all patients was 76%.
- Independent predictors of shorter CSS identified were low hemoglobin, high lactate dehydrogenase (LDH), and low albumin levels.
- A 3-tiered prognostic index (low, intermediate, high risk) demonstrated significantly different 5-year CSS rates (88%, 73%, and 50%, respectively).
Conclusions:
- A simple prognostic index utilizing hemoglobin, LDH, and albumin levels effectively stratifies SMZL patients.
- This index aids in predicting survival and can inform treatment intensity and urgency.
- The developed prognostic tool is based on readily available clinical factors, facilitating its widespread application.
